SDIC Securities released a research report on April 14 stating that it gave Channing Biotech (301301.SZ) a purchase rating. The main reasons for the rating include: 1) efficient collaboration between technology platforms and industrialization bases to continuously export new varieties, and the implementation of natural products is expected to bring new volume; 2) AI empowers the accelerated formation of new quality productivity, and the company's overall R&D and industrialization capabilities are expected to be further enhanced. (Mainichi Keizai Shimbun)
国投证券4月14日发布研报称，给予川宁生物（301301.SZ）买入评级。评级理由主要包括：1）技术平台与产业化基地高效协同，持续输出新品种，天然产物落地有望带来新增量；2）AI赋能新质生产力加速形成，公司整体研发及产业化实力有望再获提升。（每日经济新闻）
SDIC Securities released a research report on April 14 stating that it gave Channing Biotech (301301.SZ) a purchase rating. The main reasons for the rating include: 1) efficient collaboration between technology platforms and industrialization bases to con
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated